Feed excerpt — reported by The Hill
The Food and Drug Administration (FDA) on Monday required pharmaceutical companies to warn patients and healthcare providers of a potential increased risk of a serious eye condition associated with the use of GLP-1 drugs for weight loss and diabetes. Non-arteritic anterior ischemic optic neuropathy (NAION), often referred to as an "eye stroke,” is a rare condition…
MAP records observable characteristics of the original article (publisher, author, date, references, framing cues). MAP does not verify the article’s claims or score it. Read the full original story at The Hill →